Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Psychopharmacology for Dermatologists

Description

In this presentation on psychopharmacology tailored for dermatologists, the speaker emphasizes the importance and legality of using psychotropic medications within dermatology. Despite the lack of advertising for psychiatric medications in dermatological journals, the speaker assures attendees that it's both ethical and common for non-psychiatrists, including dermatologists, to prescribe these treatments. The talk focuses on key psychopharmacological agents useful for managing anxiety, depression, and OCD, such as benzodiazepines (like Xanax and lorazepam), non-benzodiazepines (like buspirone), and antidepressants (like doxepin and paroxetine). Key recommendations include starting with low doses and then titrating up to the therapeutic level, as well as tapering off medications gradually rather than stopping abruptly. The speaker also mentions how certain agents, such as doxepin, can be particularly beneficial for both anxiety and dermatological symptoms like itching. The overall message encourages dermatologists to feel comfortable with these medications by focusing on a few effective and easily manageable options, minimizing the overwhelming feeling that often comes with the extensive variety of psychotropic treatments available.

View more

Conclusions

  • Dermatologists can legally and ethically utilize psychopharmacology to enhance patient care.
  • It is advisable for dermatologists to focus on a select few psychopharmacologic agents rather than overwhelming themselves with options.
  • The recommended approach includes starting medications at low doses and titrating up as necessary.
  • When discontinuing medications, a gradual taper is essential to avoid withdrawal symptoms.
  • Certain medications, like Doxepin and Paroxetine, can effectively treat conditions like anxiety, depression, and OCD in dermatology patients.
  • Myers, B., Reddy, V., Chan, S., Thibodeaux, Q., Brownstone, N., & Koo, J. (2022). Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing. The Journal of dermatological treatment, 33(1), 87-93. https://doi.org/10.1080/09546634.2020.1762841
  • JOURNAL OF DERMATOLOGICAL TREATMENT Taylor & Francis 2025, VOL. 36, NO. 1, 2466635 Taylor & Francis Group https://doi.org/10.1080/09546634.2025.2466635